US Edition
Germany Regularly Misses Deadlines for Drug Approvals – Deutsches Ärzteblatt
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Berlin – In most cases, Germany fails to meet the specified 30-day deadline for drug approvals under the decentralized procedure. The reason for this is primarily inadequate documentation from pharmaceutical companies, as the federal government explained in its response to a parliamentary inquiry by the AfD.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
